Cancer Pain - Pipeline Review, H1 2016


#739357

149pages

Global Markets Direct

$ 2000

In Stock

Cancer Pain - Pipeline Review, H1 2016

Summary

Global Markets Directs, Cancer Pain - Pipeline Review, H1 2016, provides an overview of the Cancer Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cancer Pain
- The report reviews pipeline therapeutics for Cancer Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cancer Pain therapeutics and enlists all their major and minor projects
- The report assesses Cancer Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cancer Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cancer Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Cancer Pain Overview 12
Therapeutics Development 13
Pipeline Products for Cancer Pain - Overview 13
Pipeline Products for Cancer Pain - Comparative Analysis 14
Cancer Pain - Therapeutics under Development by Companies 15
Cancer Pain - Therapeutics under Investigation by Universities/Institutes 17
Cancer Pain - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Cancer Pain - Products under Development by Companies 22
Cancer Pain - Products under Investigation by Universities/Institutes 24
Cancer Pain - Companies Involved in Therapeutics Development 25
AngioChem Inc. 25
Aphios Corporation 26
AstraZeneca Plc 27
BCN Peptides, S.A. 28
Benitec Biopharma Limited 29
BioDelivery Sciences International, Inc. 30
ChironWells GmbH 31
Daewoong Pharmaceutical Co., Ltd. 32
Daiichi Sankyo Company, Limited 33
Fujimoto Pharmaceutical Corporation 34
Grunenthal GmbH 35
GW Pharmaceuticals Plc 36
Hisamitsu Pharmaceutical Co., Inc. 37
Immupharma Plc 38
IntelGenx Corp. 39
Kineta, Inc. 40
Kolon Life Science, Inc. 41
Neurocentrx Pharma Ltd. 42
Nippon Kayaku Co., Ltd. 43
Orion Oyj 44
Pain Therapeutics, Inc. 45
Pfizer Inc. 46
Pharmaleads SA 47
Recordati S.p.A. 48
Ribomic Inc. 49
Trillium Therapeutics Inc. 50
Virobay Inc. 51
WEX Pharmaceuticals Inc. 52
Zynerba Pharmaceuticals, Inc. 53
Cancer Pain - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
ANG-2002 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
AQU-118 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BBI-11008 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
buprenorphine hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
cebranopadol - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
crotalphine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CSTI-200 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DD-04107 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
dexmedetomidine hydrochloride - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
dronabinol - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
dronabinol - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Drug for Cancer Neuropathic Pain - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
DWJ-208 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
fentanyl - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
fentanyl citrate - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
fentanyl citrate - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
fentanyl citrate - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
HP-3150 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
HS-198 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
hydromorphone hydrochloride - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
INT-0010 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
IPP-102199 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
KLS-2020 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
methadone hydrochloride - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
nabiximols - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Nervarna - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Peptide to Target CANP for Cardiovasclar and Cancer Pain - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
PL-265 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Q-201 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
QX-314 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
RBM-004 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
RBM-007 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
saracatinib difumarate - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Small Molecules for Pancreatic Cancer and Perineural Invasion - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
tanezumab - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Tetrodotoxin - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
U-2902 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
VBY-825 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
zucapsaicin - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
ZYN-001 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Cancer Pain - Recent Pipeline Updates 123
Cancer Pain - Dormant Projects 137
Cancer Pain - Discontinued Products 141
Cancer Pain - Product Development Milestones 142
Featured News & Press Releases 142
Mar 31, 2016: Daiichi Sankyo Announces Application in Japan for Manufacturing and Sales Approval of Narcotic Analgesic Hydromorphone Hydrochloride 142
Oct 27, 2015: GW Pharmaceuticals and Otsuka Announce Results From Two Remaining Sativex Phase 3 Cancer Pain Trials 142
Aug 13, 2015: Biodelivery Sciences Announces FDA Approval Of New Formulation Of Onsolis (Fentanyl Buccal Soluble Film) CII 143
Jan 27, 2015: BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda 144
Apr 28, 2014: Hospira Files Petition Against Aurobindo Over Patent Infringement 145
Apr 28, 2014: GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain 145
Feb 18, 2014: Preclinical Data on Angiochem Pain Program Published in Journal of Clinical Investigation 146
Dec 05, 2013: Orion settles patent dispute over the proprietary drug Precedex 146
Jul 29, 2013: BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan 147
Apr 03, 2013: GW Pharma Receives US Patent Allowance For Delivery Of Sativex Formulation 147
Appendix 148
Methodology 148
Coverage 148
Secondary Research 148
Primary Research 148
Expert Panel Validation 148
Contact Us 148
Disclaimer 149

List of Tables
Number of Products under Development for Cancer Pain, H1 2016 13
Number of Products under Development for Cancer Pain - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Comparative Analysis by Unknown Stage Development, H1 2016 21
Products under Development by Companies, H1 2016 22
Products under Development by Companies, H1 2016 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2016 24
Cancer Pain - Pipeline by AngioChem Inc., H1 2016 25
Cancer Pain - Pipeline by Aphios Corporation, H1 2016 26
Cancer Pain - Pipeline by AstraZeneca Plc, H1 2016 27
Cancer Pain - Pipeline by BCN Peptides, S.A., H1 2016 28
Cancer Pain - Pipeline by Benitec Biopharma Limited, H1 2016 29
Cancer Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2016 30
Cancer Pain - Pipeline by ChironWells GmbH, H1 2016 31
Cancer Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 32
Cancer Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 33
Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corporation, H1 2016 34
Cancer Pain - Pipeline by Grunenthal GmbH, H1 2016 35
Cancer Pain - Pipeline by GW Pharmaceuticals Plc, H1 2016 36
Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016 37
Cancer Pain - Pipeline by Immupharma Plc, H1 2016 38
Cancer Pain - Pipeline by IntelGenx Corp., H1 2016 39
Cancer Pain - Pipeline by Kineta, Inc., H1 2016 40
Cancer Pain - Pipeline by Kolon Life Science, Inc., H1 2016 41
Cancer Pain - Pipeline by Neurocentrx Pharma Ltd., H1 2016 42
Cancer Pain - Pipeline by Nippon Kayaku Co., Ltd., H1 2016 43
Cancer Pain - Pipeline by Orion Oyj, H1 2016 44
Cancer Pain - Pipeline by Pain Therapeutics, Inc., H1 2016 45
Cancer Pain - Pipeline by Pfizer Inc., H1 2016 46
Cancer Pain - Pipeline by Pharmaleads SA, H1 2016 47
Cancer Pain - Pipeline by Recordati S.p.A., H1 2016 48
Cancer Pain - Pipeline by Ribomic Inc., H1 2016 49
Cancer Pain - Pipeline by Trillium Therapeutics Inc., H1 2016 50
Cancer Pain - Pipeline by Virobay Inc., H1 2016 51
Cancer Pain - Pipeline by WEX Pharmaceuticals Inc., H1 2016 52
Cancer Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 53
Assessment by Monotherapy Products, H1 2016 54
Number of Products by Stage and Target, H1 2016 56
Number of Products by Stage and Mechanism of Action, H1 2016 59
Number of Products by Stage and Route of Administration, H1 2016 62
Number of Products by Stage and Molecule Type, H1 2016 64
Cancer Pain Therapeutics - Recent Pipeline Updates, H1 2016 123
Cancer Pain - Dormant Projects, H1 2016 137
Cancer Pain - Dormant Projects (Contd..1), H1 2016 138
Cancer Pain - Dormant Projects (Contd..2), H1 2016 139
Cancer Pain - Dormant Projects (Contd..3), H1 2016 140
Cancer Pain - Discontinued Products, H1 2016 141

List of Figures
Number of Products under Development for Cancer Pain, H1 2016 13
Number of Products under Development for Cancer Pain - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Early Stage Products, H1 2016 20
Assessment by Monotherapy Products, H1 2016 54
Number of Products by Top 10 Targets, H1 2016 55
Number of Products by Stage and Top 10 Targets, H1 2016 55
Number of Products by Top 10 Mechanism of Actions, H1 2016 58
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 58
Number of Products by Top 10 Routes of Administration, H1 2016 61
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 61
Number of Products by Molecule Types, H1 2016 63
Number of Products by Stage and Molecule Types, H1 2016 63